1. Targeting the Ubiquitin System in Glioblastoma
   Nico Scholz et al, 2020, Frontiers in Oncology CrossRef
2. Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma
   Shabierjiang Jiapaer et al, 2020, Current Pharmaceutical Design CrossRef
3. Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer
   Pierre Gâtel et al, 2020, Proteostasis and Disease CrossRef
4. Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective
   Sho Tamai et al, 2020, Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications CrossRef
5. Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer
   Monserrat Olea-Flores et al, 2019, International Journal of Molecular Sciences CrossRef
6. RETRACTED ARTICLE: LncRNA RP11-84E24.3 drives tumorigenesis and epithelial-to-mesenchymal transition of glioma cells by promoting TFAP2C-mediated activation of SNAI1
   Lisha Chang et al, 2021, Journal of Neuro-Oncology CrossRef
7. ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression
   Kang Yang et al, 2022, Journal of Neuro-Oncology CrossRef
8. Promising Prognosis Marker Candidates on the Status of Epithelial–Mesenchymal Transition and Glioma Stem Cells in Glioblastoma
   Yasuo Takashima et al, 2019, Cells CrossRef
9. FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling
   Ying Chen et al, 2020, Biology Open CrossRef
10. SUMF1 overexpression promotes tumorous cell growth and migration and is correlated with the immune status of patients with glioma
    Ping Zhang et al, 2024, Aging CrossRef